Search
Tenaya Therapeutics Inc
TNYAAdd to Watchlist
0.718USD
-0.010-1.43%
Market hours （ET）Quotes delayed by 15 min
160.93MMarket Cap
LossP/E TTM
More Details of Tenaya Therapeutics Inc Company
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Tenaya Therapeutics Inc Profile
Ticker SymbolTNYA
Company nameTenaya Therapeutics Inc
IPO dateJul 30, 2021
CEOAli (Faraz)
Number of employees97
Security typeOrdinary Share
Fiscal year-endJul 30
Address171 Oyster Point Blvd., Suite 500
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone14158652066
Websitehttps://www.tenayatherapeutics.com/
Ticker SymbolTNYA
IPO dateJul 30, 2021
CEOAli (Faraz)
Company Executives of Tenaya Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
118.43K
-2.86%
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
118.43K
-2.86%
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
102.58K
-3.04%
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
102.58K
-3.04%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. Deepak Srivastava, M.D.
Dr. Deepak Srivastava, M.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey T. (Jeff) Walsh
Mr. Jeffrey T. (Jeff) Walsh
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
118.43K
-2.86%
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
118.43K
-2.86%
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
102.58K
-3.04%
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
102.58K
-3.04%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
FAQs
Who are the top five shareholders of Tenaya Therapeutics Inc?
The top five shareholders of Tenaya Therapeutics Inc are: Mr. Faraz Ali
How many institutions hold shares of Tenaya Therapeutics Inc (TNYA)?
As of 2026Q1, 270 institutions hold shares of Tenaya Therapeutics Inc, with a combined market value of approximately 117.42M, accounting for 54.11% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 48137.00.